Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
63
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ADMA Biologics, Inc.